MedTrace Logo

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

NCT03506815 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2024-07-05

Study results available
· View outcomes & findings →

Summary

Purpose of the Pilot Trial:

To determine the feasibility of conducting a multicentre randomized open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent central venous catheter (CVC) associated venous thromboembolism (VTE) among cancer patients.

Hypothesis: treatment with low dose rivaroxaban (10mg) will reduce the incidence of upper extremity venous thrombosis in a high risk population with cancer and CVC.

Conditions

  • Upper Extremity Deep Vein Thrombosis
  • Central Venous Catheter Thrombosis
  • Cancer

Interventions

DRUG

Rivaroxaban 10 MG

Rivaroxaban 10mg po daily x 90 (+/- 3 days)

Sponsors & Collaborators

  • Queen Elizabeth II Health Sciences Centre

    collaborator OTHER

  • University of Alberta

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    collaborator OTHER

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Rick T Ikesaka, MD · Ottawa Hospital Research Institute / Division of Hematology- The Ottawa Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-15
Primary Completion
2020-05-14
Completion
2020-06-14

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03506815 on ClinicalTrials.gov